Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Phase 3

Completed

• Conditions: Relapsing Multiple Sclerosis (RMS)
• Interventions: Biological: Ublituximab; Drug: Teriflunomide; Drug: Oral Placebo; Drug: IV Placebo

• Registration Number: NCT03277248
• Lead Sponsor: TG Therapeutics, Inc.

Brief Summary

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-08-25
• Study First Submitted: 2017-09-07
• Study First Submitted QC: 2017-09-07
• Study First Posted: 2017-09-11
• Primary Completion: 2020-08-04
• Study Completion: 2020-11-12
• Disposition First Submitted: 2021-05-11
• Disposition First Submitted QC: 2021-05-11
• Disposition First Posted: 2021-05-20
• Status Verified: 2021-11
• Results First Submitted: 2021-11-11
• Results First Submitted QC: 2021-11-11
• Last Update Submitted: 2021-11-11
• Results First Posted: 2021-12-06
• Last Update Posted: 2021-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 545

Inclusion Criteria

• Diagnosis of relapsing multiple sclerosis (RMS) (McDonald Criteria 2010)
• Active disease
• Expanded disability status scale (EDSS) 0 - 5.5 (inclusive) at screening

Exclusion Criteria

• Treatment with prior Anti-cluster of differentiate 20 (CD20) or other B cell directed treatment
• Treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and Stem cell transplantation
• Diagnosed with primary progressive multiple sclerosis (PPMS)
• Pregnant or nursing

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ublituximab + Oral Placebo	Ublituximab	Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
Ublituximab + Oral Placebo	Oral Placebo	Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
Teriflunomide + IV Placebo	IV Placebo	Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
Teriflunomide + IV Placebo	Teriflunomide	Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).

Primary Outcome Measures

Name	Time	Method
Annualized Relapse Rate (ARR)	Up to 96 weeks	ARR is defined as the number of Independent Relapse Adjudication Committee (IRAP)-confirmed relapses per participant year. The estimate of ARR for a treatment group is the total number of relapses for participants in the respective treatment group divided by the sum of treatment duration for participants in that specific treatment group.

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline in Brain Volume	Baseline to Week 96
Total Number of Gadolinium (Gd)-Enhancing T1-Lesions Per Magnetic Resonance Imaging (MRI) Scan Per Participant	Weeks 12, 24, 48, and 96	The total number of Gd-enhancing T1-lesions were calculated as the sum of the individual number of lesions at Weeks 12, 24, 48, and 96, divided by the total number of MRI scans of the brain.
Total Number of New and Enlarging T2 Hyperintense Lesions (NELs) Per MRI Scan Per Participant	Weeks 24, 48, and 96	The total number of NELs were calculated as the sum of the individual number of lesions at Weeks 24, 48, and 96, divided by the total number of MRI scans of the brain.
Time to Confirmed Disability Progression (CDP) for at Least 12 Weeks	Up to Week 96	12-week CDP is defined as an increase in EDSS at least 1 point higher than the baseline EDSS if the baseline EDSS is ≤5.5 or at least 0.5 higher than the baseline EDSS if the baseline EDSS is \>5.5. The EDSS is based on a standard neurological examination, (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, and cerebral) and ambulation function system assessments. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death) where higher scores indicate disability. The time to onset of 12-week CDP is the time to progression to the EDSS change defined above.
Percentage of Participants With No Evidence of Disease Activity (NEDA)	From Week 24 to Week 96	A participant with NEDA is defined as a participant without relapses confirmed by the IRAP, without MRI activities (no T1 Gd+ lesions and no new/enlarging T2 lesions), and no 12-week CDP. Any evidence of disease activity from Week 24 to Week 96 was counted as not reaching NEDA. Any evidence of disease activity before Week 24 was not counted.
Percentage of Participants With Impaired Symbol Digit Modalities Test (SDMT)	Baseline to Week 96	The SDMT involves a simple substitution task using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures. Responses are done verbally. The administration time is approximately 5 minutes. The total SDMT score for each visit ranging from 0-110 is defined as the total number of correct answers reported in the case report form (CRF), where high scores indicate better outcome. Impaired SDMT is defined as a decrease of at least 4 points from baseline at any post-baseline assessment up to the Week 96 visit.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	From the first dose of study drug through the end of the study (up to approximately 116 weeks)	An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious AE is defined as any untoward medical occurrence that: results in death, is immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, and/or causes a congenital anomaly/birth defect. TEAEs are AEs that start or worsen after receiving the study drug.

Trial Locations

Locations (2)

TG Therapeutics RMS Investigational Trial site; 🇺🇸 Seattle, Washington, United States

TG Therapeutics RMS Investigational Trial Site; 🇺🇸 Pittsburgh, Pennsylvania, United States